Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TET2 T1063Nfs*5 TET2 E1207K |
| Therapy | Dasatinib |
| Indication/Tumor Type | angioimmunoblastic T-cell lymphoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TET2 T1063Nfs*5 TET2 E1207K | angioimmunoblastic T-cell lymphoma | predicted - sensitive | Dasatinib | Case Reports/Case Series | Actionable | In a Phase I trial, four patients with relapsed/refractory angioimmunoblastic T-cell lymphoma harboring TET2 mutations and/or RHOA G17V achieved a partial response within 30 days of Sprycel (dasatinib) treatment, including one patient harboring TET2 T1063Nfs*5 and TET2 E1207K who maintained the partial response at the time of trial discontinuation (PMID: 32107212). | 32107212 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32107212) | Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. | Full reference... |